Relevance of T Lymphocytes Tumor Infiltrates CD8 and Foxp3 as Immune Prognostic Biomarker in Breast Cancer Treated by Neo Adjuvant Chemotherapy

NAActive, not recruitingINTERVENTIONAL
Enrollment

500

Participants

Timeline

Start Date

May 31, 2012

Primary Completion Date

October 31, 2015

Study Completion Date

October 31, 2025

Conditions
Breast Cancer
Interventions
OTHER

immunohistochemical detection of lymphocytes T CD8+/Foxp3 ratio

For each patients included the study, a tumour block from the initial biopsy, as well as a representative block of residual tumour (area of complete tumoral regression, area of partial tumoral regression or area of unmodified residual tumour) will be chosen by the initial pathologist in each investigating centre. Once the pathologist has verified the concordance between the images observed on the blocks sent from the investigating centres, and the associated pathology reports, immunohistochemical analysis will be performed on the slides prepared from each block.

Trial Locations (1)

21079

CGFL, Dijon

All Listed Sponsors
lead

Centre Georges Francois Leclerc

OTHER

NCT01513408 - Relevance of T Lymphocytes Tumor Infiltrates CD8 and Foxp3 as Immune Prognostic Biomarker in Breast Cancer Treated by Neo Adjuvant Chemotherapy | Biotech Hunter | Biotech Hunter